Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Piperazines Stories

2014-03-28 12:22:04

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/44vxfn/investigation ) has announced the addition of the "Investigation Report on China Imatinib Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Incidence of chronic myelogenous leukemia (CML) varies in the world. The global incidence is about 10/1,000,000 while in China it is 4/1,000,000. CML takes up about 20% of leukaemia in China...

2014-03-24 08:29:42

FAIRFIELD, N.J., March 24, 2014 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today a licensing agreement with Ferrer, a privately-held Spanish pharmaceutical company, for the commercialization rights to Ozenoxacin 1% Cream in the United States. Ozenoxacin is a novel, bactericidal non-fluorinated quinolone in development as a topical treatment for impetigo. In 2013, Ferrer successfully completed the first Phase III Clinical Trial of Ozenoxacin in adult and pediatric...

2014-03-21 12:24:00

ALBANY, New York, March 21, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Antibacterial Drugs Market (By Class- Aminoglycosides, beta-Lactams, Tetracyclines, Sulfonamides, Quinolones/Fluoroquinolones, Macrolides and Phenicols, and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global antibacterial drugs market was valued at USD 43.55billion in 2012 and is expected to...

2014-03-20 08:29:49

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy TITUSVILLE, N.J., March 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC announced today that following an Independent Data Monitoring Committee (IDMC) recommendation based on positive efficacy, it has halted early a Phase 3 clinical study of paliperidone palmitate 3-month formulation, an investigational treatment for symptoms of schizophrenia in adults. "We are...

2014-03-13 08:29:52

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, March 13, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Ferrer today announced that ADASUVE(®) inhalation powder, pre-dispensed (loxapine) is now available in Romania. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a distribution agreement with Galenica, S.A....

2014-03-13 04:23:04

TAIPEI, March 13, 2014 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that the Taiwan Food and Drug Administration (TFDA) has approved the new drug application (NDA) of Taigexyn(® )(nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn(®). An NDA for Taigexyn(® ) was also submitted to China FDA (CFDA) in...

2014-03-03 23:21:45

Transparency Market Research adds new "Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" market research report to its report store. Browse the report with request TOC; visit http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html Albany, NY (PRWEB) March 03, 2014 According to a new market report published by...

2014-02-26 16:26:01

DUBLIN, February 26, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/khhjl8/erectile) has announced the addition of the "Erectile Dysfunction Drugs Market - Forecast to 2019" [http://www.researchandmarkets.com/research/khhjl8/erectile ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the...

2014-02-24 08:29:21

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2014 /PRNewswire/ -- Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics in cancer, today announced the commencement of patient dosing in its first Phase 1 study of CB-839 in patients with advanced solid tumors. CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and...

2014-02-20 23:23:30

Drug Allegedly Linked to Serious Muscle Problems and Nerve Damage Dallas, TX (PRWEB) February 20, 2014 The national law firm of Baron and Budd is now representing clients filing lawsuits against the maker of Cipro, an antibiotic that has been allegedly linked to nerve damage and peripheral neuropathy. This is a muscle condition that can lead to several problems, including difficulty walking, significant pain and arm and leg numbness. Cipro, the brand name for the drug ciprofloxacin, is...